An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2017
At a glance
- Drugs H3B 6527 (Primary)
- Indications Cholangiocarcinoma; Liver cancer
- Focus Adverse reactions
- Sponsors H3 Biomedicine
- 15 Sep 2017 Planned number of patients changed from 90 to 105.
- 16 Dec 2016 Planned End Date changed from 1 May 2019 to 1 Jan 2019.
- 19 Jul 2016 New trial record